Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail shows promise in liver cancer fight

NCT ID NCT05301842

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study tests whether adding three drugs (durvalumab, tremelimumab, and lenvatinib) to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. About 760 participants worldwide will receive either TACE alone or TACE plus the drug combination. The main goal is to see if the combo delays cancer growth or improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

760 people

The number who actually took part.

Started

Mar 2022

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * No evidence of extrahepatic disease * Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE * Child Pugh score class A * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment * Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria * Adequate organ and marrow function Exclusion Criteria: * History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardia arrhythmia * History of hepatic encephalopathy * Major portal vein thrombosis visible on baseline imaging * Uncontrolled arterial hypertension * Co-infection with HBV and HDV

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Research Site

    Birmingham, Alabama, 35233, United States

  • Research Site

    Mobile, Alabama, 36607, United States

  • Research Site

    Yuma, Arizona, 85364, United States

  • Research Site

    Glendale, California, 91204, United States

  • Research Site

    Atlanta, Georgia, 30318, United States

  • Research Site

    Baltimore, Maryland, 21201, United States

  • Research Site

    Santa Fe, New Mexico, 87505, United States

  • Research Site

    Commack, New York, 11725, United States

  • Research Site

    New York, New York, 10029, United States

  • Research Site

    Memphis, Tennessee, 38104, United States

  • Research Site

    Dallas, Texas, 75235, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Brussels, 1070, Belgium

  • Research Site

    Ghent, 9000, Belgium

  • Research Site

    Barretos, 14784-400, Brazil

  • Research Site

    Brasília, 71681-603, Brazil

  • Research Site

    Niterói, 24020-096, Brazil

  • Research Site

    Porto Alegre, 91350-200, Brazil

  • Research Site

    Rio de Janeiro, 20231-050, Brazil

  • Research Site

    Santa Maria, 97015-450, Brazil

  • Research Site

    Santo André, 09060-650, Brazil

  • Research Site

    São Paulo, 04014-002, Brazil

  • Research Site

    Vitória, 29043-272, Brazil

  • Research Site

    Calgary, Alberta, T2N 5G2, Canada

  • Research Site

    Halifax, Nova Scotia, B3H 2Y9, Canada

  • Research Site

    Kingston, Ontario, K7L 5P9, Canada

  • Research Site

    Ottawa, Ontario, K1H 8L6, Canada

  • Research Site

    Toronto, Ontario, M4N 3M5, Canada

  • Research Site

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    Montreal, Quebec, H2X 3E4, Canada

  • Research Site

    Montreal, Quebec, H4A 3J1, Canada

  • Research Site

    Beijing, 100021, China

  • Research Site

    Beijing, 100069, China

  • Research Site

    Beijing, 100142, China

  • Research Site

    Changchun, 130021, China

  • Research Site

    Changsha, 410013, China

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Fuzhou, 350001, China

  • Research Site

    Fuzhou, 350011, China

  • Research Site

    Guangzhou, 510060, China

  • Research Site

    Guangzhou, 510515, China

  • Research Site

    Haikou, 570311, China

  • Research Site

    Hangzhou, 310022, China

  • Research Site

    Harbin, 150081, China

  • Research Site

    Hefei, 230001, China

  • Research Site

    Lanzhou, 730030, China

  • Research Site

    Lishui, 323000, China

  • Research Site

    Nanchang, 330006, China

  • Research Site

    Nanjing, 210002, China

  • Research Site

    Nantong, 226361, China

  • Research Site

    Neijiang, 641000, China

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Suzhou, 215004, China

  • Research Site

    Tianjin, 300170, China

  • Research Site

    Wenzhou, 325000, China

  • Research Site

    Wuhan, 430010, China

  • Research Site

    Wuhan, 430022, China

  • Research Site

    Xi'an, 710000, China

  • Research Site

    Zhengzhou, 450008, China

  • Research Site

    Zhuhai, 519000, China

  • Research Site

    Al Mansurah, 7650001, Egypt

  • Research Site

    Cairo, 11451, Egypt

  • Research Site

    Shebeen El Kom, 32511, Egypt

  • Research Site

    Angers, 49933, France

  • Research Site

    Clichy, 92110, France

  • Research Site

    Créteil, 94010, France

  • Research Site

    Montpellier, 34295, France

  • Research Site

    Nantes, 44093, France

  • Research Site

    Nice, 06200, France

  • Research Site

    Paris, 75013, France

  • Research Site

    Strasbourg, 67091, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Vandœuvre-lès-Nancy, 54511, France

  • Research Site

    Bonn, 53127, Germany

  • Research Site

    Chemnitz, 09116, Germany

  • Research Site

    Dresden, 01307, Germany

  • Research Site

    Düsseldorf, 40225, Germany

  • Research Site

    Frankfurt, 60596, Germany

  • Research Site

    Göttingen, 37075, Germany

  • Research Site

    Hamburg, 22291, Germany

  • Research Site

    Hanover, 30625, Germany

  • Research Site

    Heidelberg, 69120, Germany

  • Research Site

    Kiel, 24105, Germany

  • Research Site

    Leipzig, 04103, Germany

  • Research Site

    Magdeburg, 39120, Germany

  • Research Site

    Ulm, 89081, Germany

  • Research Site

    Ahmedabad, 380054, India

  • Research Site

    Ahmedabad, 380060, India

  • Research Site

    Bangalore, 560027, India

  • Research Site

    Delhi, 110029, India

  • Research Site

    Hyderabad, 500032, India

  • Research Site

    Jaipur, 302022, India

  • Research Site

    Kolkata, 700099, India

  • Research Site

    Mumbai, 400012, India

  • Research Site

    New Delhi, 110 085, India

  • Research Site

    New Delhi, 110005, India

  • Research Site

    Arezzo, 52100, Italy

  • Research Site

    Florence, 50134, Italy

  • Research Site

    Milan, 20132, Italy

  • Research Site

    Milan, 20133, Italy

  • Research Site

    Roma, 00128, Italy

  • Research Site

    Rozzano, 20089, Italy

  • Research Site

    Tricase, 73039, Italy

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Fukuoka, 810-8563, Japan

  • Research Site

    Hiroshima, 734-8551, Japan

  • Research Site

    Kashihara-shi, 634-8522, Japan

  • Research Site

    Kashiwa, 277-8577, Japan

  • Research Site

    Kumamoto, 860-8556, Japan

  • Research Site

    Mitaka-shi, 181-8611, Japan

  • Research Site

    Morioka, 028-3695, Japan

  • Research Site

    Musashino-shi, 180-8610, Japan

  • Research Site

    Okayama, 700-8558, Japan

  • Research Site

    Osaka, 543-8555, Japan

  • Research Site

    Osaka, 545-8586, Japan

  • Research Site

    Osakasayama-shi, 589-8511, Japan

  • Research Site

    Sapporo, 006-8555, Japan

  • Research Site

    Sendai, 981-0914, Japan

  • Research Site

    Sunto-gun, 411-8777, Japan

  • Research Site

    Tokushima, 770-8503, Japan

  • Research Site

    Tsu, 514-8507, Japan

  • Research Site

    Yokohama, 241-8515, Japan

  • Research Site

    Bandar Puncak Alam, 42300, Malaysia

  • Research Site

    George Town, 10450, Malaysia

  • Research Site

    Kuala Lumpur, 59100, Malaysia

  • Research Site

    Kuala Selangor, 62250, Malaysia

  • Research Site

    Kuching, 93586, Malaysia

  • Research Site

    Guadalajara, Jalisco, 44280, Mexico

  • Research Site

    México, 1400, Mexico

  • Research Site

    San Luis Potosí City, 78209, Mexico

  • Research Site

    Tuxtla Gutiérrez, 29090, Mexico

  • Research Site

    Davao City, 8000, Philippines

  • Research Site

    Makati, 1229, Philippines

  • Research Site

    Manila, 1003, Philippines

  • Research Site

    Pasig, 1600, Philippines

  • Research Site

    Quezon City, 1112, Philippines

  • Research Site

    Lisbon, 1649-035, Portugal

  • Research Site

    Vila Real, 5000-508, Portugal

  • Research Site

    Hato Rey Central, 00917, Puerto Rico

  • Research Site

    San Juan, 00927, Puerto Rico

  • Research Site

    Jeddah, 22384, Saudi Arabia

  • Research Site

    Riyadh, 12713, Saudi Arabia

  • Research Site

    Busan, 49241, South Korea

  • Research Site

    Daegu, 42601, South Korea

  • Research Site

    Goyang-si, 10408, South Korea

  • Research Site

    Junggu, 41944, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Córdoba, 14004, Spain

  • Research Site

    Donostia / San Sebastian, 20014, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Taichung, 40447, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 70403, Taiwan

  • Research Site

    Taipei, 100, Taiwan

  • Research Site

    Taipei, TAIWAN, Taiwan

  • Research Site

    Taoyuan, 333, Taiwan

  • Research Site

    Bangkok, 10210, Thailand

  • Research Site

    Bangkok, 10300, Thailand

  • Research Site

    Bangkok, 10400, Thailand

  • Research Site

    Bangkok, 10700, Thailand

  • Research Site

    Chiang Mai, 50200, Thailand

  • Research Site

    Hat Yai, 90110, Thailand

  • Research Site

    Khon Kaen, 40002, Thailand

  • Research Site

    Hanoi, 100000, Vietnam

  • Research Site

    Hà Nội, 100000, Vietnam

  • Research Site

    Ho Chi Minh City, 700000, Vietnam

  • Research Site

    Ho Chi Minh City, 70000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.